rs369790992
Variant summary
Our verdict is Uncertain significance. Variant got 2 ACMG points: 2P and 0B. PM1
The NM_000256.3(MYBPC3):c.2269G>A(p.Val757Met) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000663 in 1,613,958 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Uncertain significance (★★). Synonymous variant affecting the same amino acid position (i.e. V757V) has been classified as Likely benign.
Frequency
Consequence
NM_000256.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 2 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
MYBPC3 | NM_000256.3 | c.2269G>A | p.Val757Met | missense_variant | 23/35 | ENST00000545968.6 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
MYBPC3 | ENST00000545968.6 | c.2269G>A | p.Val757Met | missense_variant | 23/35 | 5 | NM_000256.3 | P4 | |
MYBPC3 | ENST00000399249.6 | c.2269G>A | p.Val757Met | missense_variant | 22/34 | 5 | A2 | ||
MYBPC3 | ENST00000544791.1 | c.2269G>A | p.Val757Met | missense_variant, NMD_transcript_variant | 23/27 | 5 |
Frequencies
GnomAD3 genomes AF: 0.0000131 AC: 2AN: 152254Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000642 AC: 16AN: 249212Hom.: 0 AF XY: 0.0000370 AC XY: 5AN XY: 135200
GnomAD4 exome AF: 0.0000718 AC: 105AN: 1461704Hom.: 0 Cov.: 31 AF XY: 0.0000619 AC XY: 45AN XY: 727136
GnomAD4 genome AF: 0.0000131 AC: 2AN: 152254Hom.: 0 Cov.: 32 AF XY: 0.0000134 AC XY: 1AN XY: 74376
ClinVar
Submissions by phenotype
not specified Uncertain:2
Uncertain significance, no assertion criteria provided | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Feb 12, 2013 | proposed classification - variant undergoing re-assessment, contact laboratory - |
Uncertain significance, no assertion criteria provided | clinical testing | Stanford Center for Inherited Cardiovascular Disease, Stanford University | Nov 16, 2011 | Note this variant was found in clinical genetic testing performed by one or more labs who may also submit to ClinVar. Thus any internal case data may overlap with the internal case data of other labs. The interpretation reviewed below is that of the Stanford Center for Inherited Cardiovascular Disease. p. Val757Met in MYBPC3 Given the data reviewed below, we consider it a variant of uncertain significance. This variant has been reported in one case of HCM, online in the Harvard Cardiogenomics Sarcomere Mutation Database, with no clinical information provided (Mark, Seidman et al 2005). This variant has also been reported previously in one Norwegian proband with HCM (Berge and Leren 2014). No further information was provided regarding family segregation. This variant is currently listed in ClinVar, with conflicting assessments of pathogenicity. LMM and the CSER consortium consider this to be a VUS, while GeneDx considers it to be likely disease causing (as of June 23, 2015). This is a conservative amino acid change with a neutral Valine replaced with a neutral Methionine. This variant occurs in the C5 protein domain a region of the MYBPC3 gene which is highly conserved through evolution. There are several other variants in the C5 domain that have been reported in association with HCM (p.Asn755Lys, p.Gly758Asp, p.Asp770Asn, and others). Functional studies of another variant in this region (p.Asn755Lys) indicate that the amino acid change causes thermodynamic instability which leads to complete C5 domain unfolding (Harris et al 2011). In silico analysis (MutationTaster, SIFT) predicts the amino acid change to be damaging to protein structure and function. The variant was not identified in 300 presumably healthy individuals of both Caucasian and African American ancestry at GeneDx. It is is listed in dbSNP: rs369790992. The variant is seen in 8/60,308 individuals of varying ancestries in the ExAC database. All 8 individuals were heterozygous for the p.Val757Met variant and of European descent (as of June 23, 2015). - |
not provided Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Jan 13, 2022 | Observed in individuals with HCM (Berge et al., 2014; Walsh et al., 2017); In silico analysis supports that this missense variant does not alter protein structure/function; Reported in ClinVar (ClinVar Variant ID #161309); This variant is associated with the following publications: (PMID: 25637381, 23299917, 21415409, 27532257, 28518168, 28679633, 24111713) - |
Uncertain significance, criteria provided, single submitter | not provided | Breakthrough Genomics, Breakthrough Genomics | - | - - |
Hypertrophic cardiomyopathy Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | May 05, 2022 | This sequence change replaces valine, which is neutral and non-polar, with methionine, which is neutral and non-polar, at codon 757 of the MYBPC3 protein (p.Val757Met). This variant is present in population databases (rs369790992, gnomAD 0.01%). This missense change has been observed in individual(s) with hypertrophic cardiomyopathy (PMID: 24111713, 27532257). ClinVar contains an entry for this variant (Variation ID: 161309). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Uncertain significance, criteria provided, single submitter | clinical testing | All of Us Research Program, National Institutes of Health | Dec 18, 2023 | This missense variant replaces valine with methionine at codon 757 of the MYBPC3 protein. Computational prediction suggests that this variant may not impact protein structure and function (internally defined REVEL score threshold <= 0.5, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has been reported in three individuals affected with hypertrophic cardiomyopathy (PMID: 24111713, 27532257). This variant has been identified in 16/249212 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. - |
Cardiomyopathy Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Color Diagnostics, LLC DBA Color Health | Nov 27, 2023 | This missense variant replaces valine with methionine at codon 757 of the MYBPC3 protein. Computational prediction indicates that this variant may have a neutral impact on protein structure and function. To our knowledge, functional studies have not been reported for this variant. This variant has been reported in three individuals affected with hypertrophic cardiomyopathy (PMID: 24111713, 27532257). This variant has been identified in 16/249212 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. - |
Hypertrophic cardiomyopathy 4;C3715165:Left ventricular noncompaction 10 Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Oct 29, 2021 | - - |
Primary familial hypertrophic cardiomyopathy Uncertain:1
Uncertain significance, no assertion criteria provided | research | CSER _CC_NCGL, University of Washington | Jun 01, 2014 | - - |
Cardiovascular phenotype Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Dec 11, 2023 | The p.V757M variant (also known as c.2269G>A), located in coding exon 23 of the MYBPC3 gene, results from a G to A substitution at nucleotide position 2269. The valine at codon 757 is replaced by methionine, an amino acid with highly similar properties. This variant has been reported in hypertrophic cardiomyopathy (HCM) genetic testing cohorts; however, limited clinical details were provided (Berge KE et al. Clin. Genet., 2014 Oct;86:355-60; Walsh R et al. Genet. Med., 2017 02;19:192-203). This variant has also been seen in exome cohorts, but cardiovascular history was not provided (Andreasen C et al. Eur. J. Hum. Genet., 2013 Sep;21:918-28; Amendola LM et al. Genome Res., 2015 Mar;25:305-15; Whiffin N et al. Genet. Med., 2017 10;19:1151-1158). This amino acid position is not well conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at